3European Association For The Study Of The Liver. EASL Clinical Practice Guidelines : management of chronic hepatitis B. J Hepatol, 2009,50:227-242.
4Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int, 2008,2:263-283.
8Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007,357:2576-2588.
9Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology, 2007,46 : 1695-1703.
10Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol, 2007, 5 :890-897.
5Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
6Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treat- ment in Chenese patients with chronic hepatitis B[ J]. J Gastroenterol Hepatol,2004,19 ( 11 ) : 1276-1282.
7Westland CE, Yang H, Delaney WE 4th, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients[J]. J Viral Hepat, 2005, 12:67-73.
8Vassiliadis TG, Giouleme O, Koumerkeridis G, et al. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resist- ant HBeAg-chronic hepatitis B patients : a 4-year study[ J]. J Gastro- enterol Hepatol, 2010,25 ( 1 ) :54-60.
6Committee of experts on antiviral therapy in nucleos(t)ide analogues experienced chronic hepatitis B patients.慢性乙型肝炎核苷(酸)类似物经治患者抗病毒治疗专家共识:2016年更新[J].中国肝脏病杂志(电子版),2016,8(3):15-20. 被引量:8
8Committee of experts on antiviral therapy in nucleos(t)ide analogues experienced patients with chronic hepatitis B.慢性乙型肝炎核苷(酸)类似物经治患者抗病毒治疗专家共识:2016年更新[J].中华实验和临床感染病杂志(电子版),2016,10(5):527-533. 被引量:3